{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:25:44Z","timestamp":1780471544336,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.gim.2022.10.011","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T16:02:46Z","timestamp":1670256166000},"page":"100329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-9941","authenticated-orcid":false,"given":"Timothy M.","family":"Cox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Charrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lukina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod K.","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith C.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Judith","family":"Peterschmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gim.2022.10.011_bib1","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Gaucher disease","author":"Grabowski","year":"2013"},{"issue":"6","key":"10.1016\/j.gim.2022.10.011_bib2","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","article-title":"Gaucher disease in bone: from pathophysiology to practice","volume":"34","author":"Hughes","year":"2019","journal-title":"J\u00a0Bone Miner Res"},{"issue":"suppl 1","key":"10.1016\/j.gim.2022.10.011_bib3","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1259\/bjr.75.suppl_1.750002","article-title":"Skeletal aspects of Gaucher disease: a review","volume":"75","author":"Wenstrup","year":"2002","journal-title":"Br J Radiol"},{"issue":"6","key":"10.1016\/j.gim.2022.10.011_bib4","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","article-title":"Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease","volume":"71","author":"Weinreb","year":"2007","journal-title":"Clin Genet"},{"issue":"8","key":"10.1016\/j.gim.2022.10.011_bib5","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/jbmr.1680","article-title":"Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry","volume":"27","author":"Khan","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"6","key":"10.1016\/j.gim.2022.10.011_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00223-014-9923-y","article-title":"Gaucher disease and bone manifestations","volume":"95","author":"Marcucci","year":"2014","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"10.1016\/j.gim.2022.10.011_bib7","first-page":"165","article-title":"Gaucher disease: the role of the specialist on metabolic bone diseases","volume":"12","author":"Masi","year":"2015","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"4","key":"10.1016\/j.gim.2022.10.011_bib8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ymgme.2011.08.004","article-title":"Therapeutic approaches to bone pathology in Gaucher disease: past, present and future","volume":"104","author":"Goker-Alpan","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"16","key":"10.1016\/j.gim.2022.10.011_bib9","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1001\/archinternmed.2010.302","article-title":"Type 1 Gaucher disease: significant disease manifestations in \u201casymptomatic\u201d homozygotes","volume":"170","author":"Balwani","year":"2010","journal-title":"Arch Intern Med"},{"issue":"21","key":"10.1016\/j.gim.2022.10.011_bib10","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2014macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease","volume":"324","author":"Barton","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.gim.2022.10.011_bib11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","article-title":"Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment","volume":"132","author":"Weinreb","year":"2021","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.gim.2022.10.011_bib12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.gim.2022.10.011_bib13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","article-title":"Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment","volume":"36","author":"Weinreb","year":"2013","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"3","key":"10.1016\/j.gim.2022.10.011_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ymgme.2017.12.001","article-title":"Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: the phase 3, randomized, double-blind EDGE trial","volume":"123","author":"Charrow","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"9985","key":"10.1016\/j.gim.2022.10.011_bib15","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.gim.2022.10.011_bib16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A\u00a0phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.gim.2022.10.011_bib17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.gim.2022.10.011_bib18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s13023-021-02034-6","article-title":"In-depth phenotyping for clinical stratification of Gaucher disease","volume":"16","author":"D\u2019Amore","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.gim.2022.10.011_bib19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A\u00a0specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease","volume":"91","author":"McEachern","year":"2007","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10.1016\/j.gim.2022.10.011_bib20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.2013.2","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants","volume":"93","author":"Hicks","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.gim.2022.10.011_bib21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0091270010372387","article-title":"Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers","volume":"51","author":"Peterschmitt","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"20","key":"10.1016\/j.gim.2022.10.011_bib22","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gim.2022.10.011_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ajh.25300","article-title":"Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: final results from the phase 2 trial","volume":"94","author":"Lukina","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.gim.2022.10.011_bib24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4 years of treatment","volume":"53","author":"Lukina","year":"2014","journal-title":"Blood Cells Mol Dis"},{"issue":"11","key":"10.1016\/j.gim.2022.10.011_bib25","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.24877","article-title":"Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: the phase 3 ENGAGE trial","volume":"92","author":"Mistry","year":"2017","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.gim.2022.10.011_bib26","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ajh.26276","article-title":"Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: phase 3 ENGAGE trial final results","volume":"96","author":"Mistry","year":"2021","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.gim.2022.10.011_bib27","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","article-title":"Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy","volume":"129","author":"Cox","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gim.2022.10.011_bib28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13023-019-1085-6","article-title":"Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1","volume":"14","author":"Peterschmitt","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.gim.2022.10.011_bib29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00256-007-0425-0","article-title":"Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease","volume":"37","author":"Maas","year":"2008","journal-title":"Skelet Radiol"},{"issue":"6","key":"10.1016\/j.gim.2022.10.011_bib30","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2214\/AJR.06.1410","article-title":"Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher\u2019s disease using the bone marrow burden score","volume":"188","author":"Robertson","year":"2007","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.gim.2022.10.011_bib31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2292020296","article-title":"Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging\u2014initial experience","volume":"229","author":"Maas","year":"2003","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.gim.2022.10.011_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/GIM.0b013e3181c39194","article-title":"A\u00a0validated disease severity scoring system for adults with type 1 Gaucher disease","volume":"12","author":"Weinreb","year":"2010","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gim.2022.10.011_bib33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13023-015-0280-3","article-title":"Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3)","volume":"10","author":"Weinreb","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.gim.2022.10.011_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bcmd.2010.10.010","article-title":"Potential biomarkers of osteonecrosis in Gaucher disease","volume":"46","author":"Pavlova","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"10.1016\/j.gim.2022.10.011_bib35","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-014-9711-x","article-title":"Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy","volume":"37","author":"van Dussen","year":"2014","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"8","key":"10.1016\/j.gim.2022.10.011_bib36","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2014-09-600270","article-title":"Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation","volume":"125","author":"Nair","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.gim.2022.10.011_bib37","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal immunoglobulin against lysolipids in the origin of myeloma","volume":"374","author":"Nair","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.gim.2022.10.011_bib38","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1042\/EBC20190090","article-title":"Lyso-glycosphingolipids: presence and consequences","volume":"64","author":"van Eijk","year":"2020","journal-title":"Essays Biochem"},{"issue":"16","key":"10.1016\/j.gim.2022.10.011_bib39","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.gim.2022.10.011_bib40","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ajh.24801","article-title":"Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase\/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry","volume":"92","author":"Mistry","year":"2017","journal-title":"Am J Hematol"},{"issue":"4 Suppl 5","key":"10.1016\/j.gim.2022.10.011_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","article-title":"Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients","volume":"41","author":"Weinreb","year":"2004","journal-title":"Semin Hematol"},{"issue":"4 suppl 5","key":"10.1016\/j.gim.2022.10.011_bib42","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.gim.2022.10.011_bib43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","article-title":"Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease","volume":"22","author":"Wenstrup","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"issue":"9","key":"10.1016\/j.gim.2022.10.011_bib44","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/ajh.25875","article-title":"Real-world effectiveness of eliglustat in treatment-naive and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry","volume":"95","author":"Mistry","year":"2020","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.gim.2022.10.011_bib45","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbadis.2007.04.002","article-title":"Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease","volume":"1772","author":"van Breemen","year":"2007","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"10.1016\/j.gim.2022.10.011_bib46","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00256-014-1891-9","article-title":"Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat","volume":"43","author":"Kamath","year":"2014","journal-title":"Skeletal Radiol"},{"issue":"1","key":"10.1016\/j.gim.2022.10.011_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17530059.2012.626402","article-title":"Biomarkers for osteonecrosis in Gaucher disease","volume":"6","author":"Pavlova","year":"2012","journal-title":"Expert Opin Med Diagn"},{"issue":"16","key":"10.1016\/j.gim.2022.10.011_bib48","doi-asserted-by":"crossref","first-page":"E3285","DOI":"10.1073\/pnas.1618133114","article-title":"Intracellular metabolite beta-glucosylceramide is an endogenous Mincle ligand possessing immunostimulatory activity","volume":"114","author":"Nagata","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.gim.2022.10.011_bib49","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1172\/JCI134214","article-title":"Osteocyte necrosis triggers osteoclast-mediated bone loss through macrophage-inducible C-type lectin","volume":"130","author":"Andreev","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.gim.2022.10.011_bib50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13023-020-01656-6","article-title":"The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients","volume":"16","author":"Deegan","year":"2021","journal-title":"Orphanet J Rare Dis"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360022009972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360022009972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:55:18Z","timestamp":1761098118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360022009972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1098360022009972"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2022.10.011","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2022.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.","name":"copyright","label":"Copyright"}],"article-number":"100329"}}